Abstract
The effects of proliferative, apoptotic and anti-proliferative stimuli on interferon regulatory factor 4 (IRF4) expression by Reed-Sternberg (RS) cells were analysed using a panel of Hodgkin lymphoma (HL)-derived cell lines. IRF4 expressed by HL cells was consistently upregulated after CD40 engagement; IRF4 was downregulated by agonistic anti-CD95 antibodies in the FAS-sensitive HDLM-2 cells and after treatment with Adriamycin and Dacarbazine, two chemotherapic agents commonly used for HL treatment. These results demonstrated, for the first time, that IRF4 was up-modulated by CD40 engagement, and down-modulated by apoptotic and anti-proliferative signals, suggesting an involvement of IRF4 also in HL pathobiology.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibiotics, Antineoplastic / pharmacology
-
Antineoplastic Agents, Alkylating / pharmacology
-
Apoptosis / drug effects
-
Apoptosis / immunology*
-
CD40 Ligand / immunology*
-
Cell Proliferation
-
Dacarbazine / pharmacology
-
Dose-Response Relationship, Drug
-
Doxorubicin / pharmacology
-
Gene Expression Regulation, Neoplastic / drug effects
-
Gene Expression Regulation, Neoplastic / immunology
-
Hodgkin Disease / immunology*
-
Hodgkin Disease / pathology
-
Humans
-
Interferon Regulatory Factors / metabolism*
-
Reed-Sternberg Cells / immunology
-
Tumor Cells, Cultured
Substances
-
Antibiotics, Antineoplastic
-
Antineoplastic Agents, Alkylating
-
Interferon Regulatory Factors
-
interferon regulatory factor-4
-
CD40 Ligand
-
Dacarbazine
-
Doxorubicin